Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

BACKGROUND: GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivalent influenza vaccine (IIV4) to harmonize the process among different strains, resulting in an increased number of finished vaccine doses, while compensating for the change from...

Descripción completa

Detalles Bibliográficos
Autores principales: Claeys, Carine, Drame, Mamadou, García-Sicilia, José, Zaman, Khalequ, Carmona, Alfonso, Tran, Phu My, Miranda, Mariano, Martinón-Torres, Federico, Thollot, Franck, Horn, Michael, Schwarz, Tino F., Behre, Ulrich, Merino, José M., Sadowska-Krawczenko, Iwona, Szymański, Henryk, Schu, Peter, Neumeier, Elisabeth, Li, Ping, Jain, Varsha K., Innis, Bruce L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907359/
https://www.ncbi.nlm.nih.gov/pubmed/29669531
http://dx.doi.org/10.1186/s12879-018-3079-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907359/
https://www.ncbi.nlm.nih.gov/pubmed/29669531
http://dx.doi.org/10.1186/s12879-018-3079-8

Ejemplares similares